User profiles for Kyaw Z. Thein
 | Kyaw Zin TheinComprehensive Cancer Centers of Nevada - Central Valley Verified email at usoncology.com Cited by 1580 |
Copper deficiency anemia
Copper is a crucial micronutrient needed by animals and humans for proper organ function
and metabolic processes such as hemoglobin synthesis, as a neurotransmitter, for iron …
and metabolic processes such as hemoglobin synthesis, as a neurotransmitter, for iron …
Precision therapy for RET-altered cancers with RET inhibitors
Rearranged during transfection (RET) is involved in the physiological development of some
organ systems. Activating RET alterations via either gene fusions or point mutations are …
organ systems. Activating RET alterations via either gene fusions or point mutations are …
Therapeutics targeting mutant KRAS
KZ Thein, AB Biter, DS Hong - Annual review of medicine, 2021 - annualreviews.org
Aberrations in rat sarcoma (RAS) viral oncogene are the most prevalent and best-known
genetic alterations identified in human cancers. Indeed, RAS drives tumorigenesis as one of the …
genetic alterations identified in human cancers. Indeed, RAS drives tumorigenesis as one of the …
Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers
PURPOSE DNA polymerase epsilon is critical to DNA proofreading and replication. Mutations
in POLE have been associated with hypermutated tumors and antitumor response to …
in POLE have been associated with hypermutated tumors and antitumor response to …
Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center
Study objective Cancer immunotherapy is evolving rapidly and is transforming cancer care.
During the last decade, immune checkpoint therapies have been developed to enhance the …
During the last decade, immune checkpoint therapies have been developed to enhance the …
Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer
KZ Thein, AB Biter, KC Banks, AW Duda… - JCO Precision …, 2022 - ascopubs.org
PURPOSE KRAS is the most mutated proto-oncogene that has been identified in cancer, and
treatment of patients with KRAS mutations remains an arduous challenge. Recently, KRAS …
treatment of patients with KRAS mutations remains an arduous challenge. Recently, KRAS …
Tissue-agnostic drug development: a new path to drug approval
In recent years, there has been remarkable progress in our understanding of cancer biology,
host responses, and the concept of precision oncology. These advances have focused …
host responses, and the concept of precision oncology. These advances have focused …
Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development
KZ Thein, YM Myat, BS Park, K Panigrahi… - Cancers, 2024 - pmc.ncbi.nlm.nih.gov
Simple Summary Precision oncology is at the forefront of personalized cancer care, utilizing
tumor-agnostic therapies that target specific biomarkers, such as tumor mutational burden, …
tumor-agnostic therapies that target specific biomarkers, such as tumor mutational burden, …
[HTML][HTML] Tissue-agnostic targeting of neurotrophic tyrosine receptor kinase fusions: Current approvals and future directions
Simple Summary There has recently been an interest in drugs that work across the pan-cancer
spectrum and show antitumor activity based on biomarkers rather than histology. In this …
spectrum and show antitumor activity based on biomarkers rather than histology. In this …
First‐in‐human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignancies
Background This was a phase I/IIa study to investigate the tolerability, efficacy and
pharmacokinetics (PK)/ pharmacodynamics (PD) of CRLX301, CDP-based nanoparticle formulation …
pharmacokinetics (PK)/ pharmacodynamics (PD) of CRLX301, CDP-based nanoparticle formulation …